 NEW YORK, Aug. 25, 2021 PRNewswire -- Renovacor, Inc. Renovacor, an earlystage biotechnology company developing adeno-associated virus AAVbased gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer CSO, effective as of September 1, 2021. 